Los Angeles, CA, 8/7/2023 – T&J Brothers Group, LLC, a privately held investment company and real estate consultancy firm with a strong commitment to social responsibility, proudly announces a significant milestone within its portfolio. Marizyme, Inc., a company in which T&J Brothers Group invested three years ago, has filed an S1 for uplisting to senior exchange such as Nasdaq or the NYSE in July 2023, and being listed as one of its principal stockholders (1). T&J Brothers Group is excited to witness Marizyme’s progress and looks forward to the potential growth and positive impact of this development in the healthcare innovation sector.
Marizyme, Inc. (“Marizyme” or the “Company”) (OTCQB: MRZM) is a multi-technology biomedical company focused on the accelerated development and commercialization of medical technologies that improve patient health outcomes, announced today that it has recently received additional granted patents and notices of allowance for three of its core technologies in several key markets further strengthening the Company’s intellectual property.
Marizyme’s flagship product, DuraGraft®, and the company has granted patents covering this product in the United States, India, South Korea, and Vietnam. The issued patents and allowed patent applications protect Marizyme’s flagship commercial product DuraGraft, a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries that is authorized for use in Europe and other countries outside of the United States.
(DuraGraft®, is an investigational product used during Coronary Artery Bypass Grafting (CABG) surgery.)
Building on their international success, Marizyme is looking to enter the US market. Yet, DuraGraft is currently under review by the FDA for authorization in the United States.
“The countries in which patents are allowed or granted represent large and rapidly expanding cardiac surgery markets and significantly expand our patent estate for DuraGraft and present tremendous commercialization and licensing opportunities for us,” said David Barthel, Marizyme’s CEO.
T&J Brothers group has beliefs in making a meaningful impact on society and the environment centers around responsible and sustainable practices, prioritizing the well-being of current and future generations. Marizyme inc has being one of their key investments.
They are convinced that healthcare innovation for coronary artery disease treatments offers significant benefits by delivering better and accessible medical solutions, improving patient outcomes, and potentially alleviating the strain on healthcare systems through more effective prevention and management of this common cardiovascular condition.
About T&J Brothers group:
T&J Brothers Group is an California llc, founded by zhonghao chen and xingyu yang, the company is a private investment company and real estate consultancy firm. With an active pursuit of both private and public investment opportunities worldwide, the company focuses on long-term structural value investing and industrial innovation across sectors like biopharmaceuticals, life health, and hard technology. Its investment portfolio encompasses early-stage venture capital, public companies, and merger and acquisition deals. Alongside offering business consulting for small enterprises and consultancy services for small-scale real estate investments, T&J Brothers Group remains committed to Environmental, Social, and Governance (ESG) principles. They prioritize sustainability, reduce their carbon footprint, preserve biodiversity, and embrace renewable energy. The company promotes diversity and inclusion in the workplace, engages with local communities for social development, and upholds ethical practices with transparency through a diverse and independent board.
Source:
1: SEC: Marizyme S1 filing(Pg. 126) : https://d18rn0p25nwr6d.cloudfront.net/CIK-0001413754/14bcff86-f30f-4a3a-9848-908e7f7ec436.pdf
www.tjbrothers.com/about-us
www.globenewswire.com/news-release/2023/05/10/2665486/0/en/Marizyme-Announces-IP-Developments-for-DuraGraft-and-Its-Pipeline-Products.html
medcitynews.com/?sponsored_content=new-technology-for-cabg-surgery-procedures